Official reports cite that the centre has approved the tariff of Bharat Biotech’s nasal Covid vaccine iNCOVACC to be available at Rs.800 for private and Rs.325 for government hospitals. Accordingly, the nasal vaccine is to be rolled out for public use in the fourth week of January.
The government of India has approved iNCOVACC as a heterogenous booster dose for those above the age of 18 years. The Union Health Ministry assured that this booster is applicable to all who have taken Covishield or Covaxin as their primary doses.
iNCOVACC turned out to become the world’s intranasal vaccine and has received both primary & heterogeneous approval. Earlier, the government allowed the use of this vaccine under restricted emergency usage.
The phase III trial of the nasal vaccine was conducted on 3,100 subjects from 14 trial cities.
Accordingly, with the approval of the nasal booster, it will be made available on the CoWIN platform with appropriate changes.
